Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 550-555
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Table 3 Results of eradication therapy
| PPI group | Vonoprazan group | P value | |
| Primary eradication therapy | |||
| ITT analysis | 73.2% (1259/1720) | 85.7% (287/335) | < 0.0001 |
| PP analysis | 76.4% (1259/1647) | 90.3% (287/318) | < 0.0001 |
| Secondary eradication therapy | |||
| ITT analysis | 89.9% (347/386) | 89.4% (59/66) | 0.87 |
| PP analysis | 92.8% (347/374) | 96.7% (59/61) | 0.4 |
- Citation: Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2016; 7(4): 550-555
- URL: https://www.wjgnet.com/2150-5349/full/v7/i4/550.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i4.550